[1] 程洋,张峰,王曦旋,等. 普萘洛尔与卡维地洛预防肝硬化患者并发食管胃静脉曲张破裂出血临床疗效比较. 实用肝脏病杂志,2023,26(2):254-257. [2] Hu XG, Dai JJ, Lu J, et al. Efficacy of transjugular intrahepatic portosystemic shunts in treating cirrhotic esophageal-gastric variceal bleeding.World J Gastrointest Surg, 2024, 16(2):471-480. [3] Tevethia HV, Pande A, Vijayaraghavan R,et al.Combination of carvedilol with variceal band ligation in prevention of first variceal bleed in Child-Turcotte-Pugh B and C cirrhosis with high-risk oesophageal varices: the 'CAVARLY TRIAL'. Gut, 2024, 73(11):1844-1853. [4] 原姗姗,刘家铭,庄坤,等. 内镜下食管静脉曲张套扎联合卡维地洛或普萘洛尔治疗肝硬化食管静脉曲张再出血的随机对照研究. 中国医药,2022,17(1):68-71. [5] Ma H, Chen J, Zhan X,et al. Platelet-to-albumin ratio:a potential biomarker for predicting all-cause and cardiovascular mortality in patients undergoing peritoneal dialysis.BMC Nephrol, 2024, 25(1):365. [6] 陈声辉,姚思思,余明. Charlson合并症指数对低位直肠癌根治术患者预后的预测价值. 癌症进展,2024,22(5):536-539. [7] Gralnek IM, Camus Duboc M, Garcia-Pagan JC,et al. Endoscopic diagnosis and management of esophagogastric variceal hemorrhage:European society of gastrointestinal endoscopy (ESGE) guideline.Endoscopy, 2022, 54(11):1094-1120. [8] 吕梦甜,孙菊,刘文宾, 等.查尔森合并症指数对重型再生障碍性贫血患者的预后价值. 中华危重症医学杂志(电子版), 2020, 1(4):277-279. [9] Fu S, Chen D, Zhang Z,et al. Predictive value of spectral computed tomography parameters in esophageal variceal rupture and bleeding in cirrhosis.Turk J Gastroenterol, 2023, 34(4):339-345. [10] Liu C, Zhang L, Zhang S, Li X, et al. Carvedilol to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by liver stiffness:study protocol for a randomied, double-blind, placebo-controlled, multicentre trial in China. BMJ Open, 2024, 14(7):e081623. [11] Xia R, Wu B, Zhou J,et al. Ascites affects the benefit of carvedilol on patients with liver cirrhosis and esophageal and gastric varices. Clin Transl Sci, 2024, 17(7):e13889. [12] Yang TC, Chen WC, Hou MC,et al. Endoscopic variceal ligation versus propranolol for the primary prevention of oesophageal variceal bleeding in patients with hepatocellular carcinoma:an open-label, two-centre, randomised controlled trial.Gut, 2024, 73(4):682-690. [13] 涂建军,方翔,蒋琪,等. 乙型肝炎肝硬化并发食管胃底静脉曲张破裂出血患者再出血影响因素及预测模型的建立. 实用肝脏病杂志,2023,26(5):686-689. [14] 叶丝陶,黄晓铨,陈世耀. 血浆纤维蛋白原水平预测乙型肝炎肝硬化患者内镜治疗后食管胃静脉曲张再出血风险效能分析. 实用肝脏病杂志,2023,26(3):392-395. [15] 贺庆娟,房英霞,刘旭臣,等. 肝硬化食管静脉曲张急诊套扎术后再出血的影响因素. 临床肝胆病杂志,2022,38(8):1801-1805. [16] 胡建,姚运河,顾宇,等. 治疗前血小板与白蛋白比值对肝硬化伴食管和胃静脉曲张出血内镜治疗短期预后的预测价值. 中国医师进修杂志,2024,47(2):144-149. [17] Gnanenthiran SR, Pennings GJ, Reddel CJ,et al. Identification of a distinct platelet phenotype in the elderly:ADP hypersensitivity coexists with platelet PAR (Protease-Activated Receptor)-1 and PAR-4-mediated thrombin resistance.Arterioscler Thromb Vasc Biol, 2022, 42(8):960-972. [18] 蔡驰宇,王连才,陶连元,等. 年龄校正的Charlson合并症指数与肝门部胆管癌患者腹腔镜手术切除后预后的关系. 中华肝胆外科杂志,2024,30(1):33-37. [19] Tarannum S, Ilyas T, Tarannum Shaik S,et al. Assessment of the Child-Pugh score, model for end-stage liver disease score, fibrosis-4 index, and AST to platelet ratio index as non-endoscopic predictors of the presence of esophageal varices and variceal bleeding in chronic liver disease patients.Cureus, 2024, 16(11):e73768. [20] Narayanan P.PAR for the liver course: Preserving platelet function mitigates outcomes in cirrhosis.Hepatology, 2024, 80(5):991-992. |